Virtual Reality-Assisted Nursing Intervention During Intrauterine Device Insertion (VR-IUD)

October 30, 2026 updated by: YASEMİN ATEŞEYAN, Mersin University

Effect of Virtual Reality-Assisted Nursing Intervention on Pain and Anxiety During Intrauterine Device Insertion: A Randomized Controlled Trial

This randomized controlled trial evaluated the effects of a virtual reality-supported nursing intervention based on Kolcaba's Comfort Theory on women's comfort, emotional state, pain and physiological parameters during intrauterine device insertion. Seventy women attending a family planning clinic were individually randomized by lottery to a virtual reality group, who received the intervention in addition to routine care, or to a control group, who received routine care only.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Study hypotheses

Compared with the control group (routine care without virtual reality), women receiving the virtual reality-assisted nursing intervention (experimental group):

  • experience a lower level of pain during the procedure;
  • experience lower levels of anxiety during the procedure;
  • exhibit a lower stress response in physiological parameters (pulse rate, blood pressure and respiratory rate);
  • experience higher levels of comfort during the procedure. Condition: Pain, anxiety, physiological parameters and comfort of women during intrauterine device (IUD) insertion Intervention: Virtual reality-assisted nursing intervention Population: Women who have decided to have an IUD inserted Note on outcomes: In the initial registration, pain was erroneously listed as the primary outcome. The primary outcome of this trial is overall comfort, measured with the General Comfort Scale total score before and after the procedure. This was corrected on October 30, 2026. Pain was assessed at all planned time points and is reported as a secondary outcome.

Study Design Study type: Interventional (clinical trial) Design: Single-center, prospective, two-arm, parallel-group randomized controlled trial Allocation: Randomized (1:1) Masking: None (open label). Because of the nature of the intervention, participants, the nurse researcher delivering the intervention and the practitioners could not be blinded. Data were coded before analysis, and the analyses were performed by a researcher who was not involved in data collection.

Setting: Family planning outpatient clinic of a women's and children's hospital, Gaziantep, Türkiye Study period: October 2024 to March 2025 Sample Size The sample size was calculated with G*Power 3.1.9.4 for a repeated-measures analysis of variance (two groups, two measurements), with a significance level of 5% (alpha = 0.05), a power of 95% and an effect size of f = 0.40. The minimum required sample was 64 women (32 per group). To allow for possible data loss, the target sample was set at 70 women (35 per group).

Participant Flow Eighty-nine women who agreed to participate were assessed for eligibility. Nineteen did not meet the eligibility criteria (visual impairment, n = 5; psychiatric disorder, n = 2; severe dizziness, n = 4; analgesic use before the procedure, n = 8). The remaining 70 women were randomized (experimental group = 35, control group = 35). No participant withdrew or was lost to follow-up, and all 70 women were included in the analysis.

Randomization and Groups Participants were individually randomized in a 1:1 ratio to the experimental or control group by lottery. Seventy identical slips of white paper, 35 labeled "experimental group" and 35 labeled "control group," were placed in a bag. After giving written informed consent and completing the baseline assessments, and before IUD insertion, each eligible woman drew one slip from the bag; drawn slips were not returned.

Given the nature of the intervention, information exchange between participants (contamination) could have influenced the results. To minimize this risk, women waited in a separate waiting area before the procedure, were called into the procedure room individually and, after the procedure, left the clinic through a separate exit that did not lead back to the waiting area.

Baseline characteristics of the groups were compared statistically, and baseline-adjusted analyses were used to account for any imbalances.

Note: An earlier version of this record described day-based allocation. This description has been corrected to reflect the individual lottery-based randomization that was actually implemented.

Intervention Experimental group (virtual reality group): In addition to routine care, women received a virtual reality-assisted nursing intervention based on Kolcaba's Comfort Theory. The nurse researcher prepared each woman for the procedure and used virtual reality to increase her comfort and reduce her anxiety. Women watched a nature-themed 360-degree video (water, forest and sky scenes) with soothing music, lasting approximately 6 minutes, through a virtual reality headset. The video was started 2 minutes before insertion and continued until it ended after insertion. The intervention was designed as a non-pharmacological nursing intervention to divert attention away from the procedure and to reduce pain and anxiety.

Control group (routine care): Women received routine care according to the clinic's standard practice, without virtual reality or any other study intervention.

All participants received a copper IUD inserted by the practitioners on duty. Materials

  1. Virtual reality headset: Samsung Gear VR (SM-R321NZWATUR), used with a smartphone
  2. Virtual reality video: "Virtual Nature 360° - 5K Nature Meditation for Daydream, Oculus, Gear VR," featuring nature scenes accompanied by calming music Data Collection Data were collected by trained researchers through face-to-face interviews in three phases; each session took approximately 15 to 20 minutes.

Before the procedure: Descriptive Characteristics Questionnaire; General Comfort Scale; visual analogue scales for anticipated pain, tension, fear/anxiety, irritability and contentment; blood pressure, pulse rate and respiratory rate. Allocation slips were drawn after these assessments.

During the procedure: pain (visual analogue scale) and pulse rate immediately after speculum insertion, tenaculum application and IUD placement.

After the procedure (5 minutes): blood pressure, pulse rate and respiratory rate; visual analogue scales for pain, tension, fear/anxiety, irritability and contentment; General Comfort Scale. Procedure duration (minutes), practitioner satisfaction and adverse events (such as dizziness, nausea and headset discomfort) were also recorded.

Vital signs were measured in both groups by the same researcher with the same device.

Data Collection Instruments Descriptive Characteristics Questionnaire: Prepared by the researchers on the basis of the literature; it covers age, education, employment, income, health insurance, obstetric history, current contraceptive use and its duration, previous IUD use, the person who decided on IUD use and negative information about IUDs received from the social environment.

General Comfort Scale: Developed by Kolcaba and adapted into Turkish, the scale consists of 48 four-point Likert-type items in three subscales (relief, ease and transcendence). Negative items are reverse-scored. Total scores range from 48 to 192, and higher scores indicate greater comfort. Cronbach's alpha was 0.85 for the Turkish version.

Visual analogue scales: Tension, fear/anxiety, irritability and contentment were each rated on a 100-mm scale from 0 (none) to 100 (most intense). Pain was rated on a 100-mm scale from 0 (no pain) to 100 (worst imaginable pain). Before the procedure, women rated on the same scale the pain they expected to feel during insertion (anticipated pain). The practitioner rated satisfaction with the procedure on a 100-mm scale from 0 (not at all satisfied) to 100 (completely satisfied).

Ethics Ethical approval was obtained from the SANKO University Clinical Research Ethics Committee (Decision No. 2023/24; December 21, 2023), together with institutional permission. The study followed the Declaration of Helsinki. Participants were informed about the aims and procedures of the study, and written informed consent was obtained from all participants.

Statistical Analysis Data were analyzed with IBM SPSS Statistics 25.0. Normality was assessed by skewness and kurtosis, homogeneity of variances by Levene's test and homogeneity of covariance matrices by Box's M test. Baseline characteristics were compared with the chi-square, Fisher's exact or Fisher-Freeman-Halton exact test and the independent-samples t-test, and standardized mean differences were calculated.

Intervention effects were estimated with analysis of covariance (ANCOVA), using the post-procedure score as the dependent variable, group as the fixed factor and the baseline score as the covariate (anticipated pain for pain after the procedure). ANCOVA assumptions (linearity, homogeneity of regression slopes, normality and homogeneity of residuals, influential observations) were checked. Sensitivity analyses included additional covariates for imbalanced baseline characteristics, heteroscedasticity-consistent (HC3) standard errors and a mixed-design repeated-measures ANOVA (group x time).

Variables not suitable for parametric testing (irritability, pain, procedure duration and practitioner satisfaction) were compared with the Mann-Whitney U test, and within-group change in pain with the Wilcoxon signed-rank test. Intraprocedural pain was compared with the Mann-Whitney U test and intraprocedural pulse rate with ANCOVA adjusted for baseline pulse rate. All tests were two-sided, and p < 0.05 was considered significant.

Study Type

Interventional

Enrollment (Actual)

70

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Gaziantep, Turkey (Türkiye), 27270
        • Women's and Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

Aged 18 years or older Sexually active Decided to undergo intrauterine device insertion after routine contraceptive counseling Suitable candidate for intrauterine device insertion on gynecological examination No communication difficulties

Exclusion Criteria:

Visual or hearing impairment Diagnosed psychiatric disorder Severe facial injury History of epilepsy or severe dizziness Analgesic use before the procedure Any contraindication to intrauterine device insertion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Virtual reality group

Intervention Type: Behavioral Intervention Name: Virtual reality-supported nursing intervention Other Intervention Names: VR-supported nursing intervention Assign to Arm: Experimental: Virtual reality group Description:Routine care plus the virtual reality-supported nursing intervention during IUD insertion.

In addition to routine care, women received a virtual reality-supported nursing intervention based on Kolcaba's Comfort Theory. The nurse prepared each woman for the procedure and used virtual reality to increase comfort and reduce anxiety. Women watched a nature-themed 360-degree video with relaxing music (approximately 6 minutes) through a head-mounted display (Samsung Gear VR), started 2 minutes before insertion and continued until the video ended.

Intervention Name: Virtual Reality Intervention

Description:

Participants in the experimental group received a virtual reality-assisted nursing intervention during intrauterine device insertion. A virtual reality headset was used to present a 3D immersive video including relaxing natural scenes and calming background music. The intervention was applied continuously throughout the procedure to distract attention from the procedure and reduce pain and anxiety.

Intervention Name: Routine Care

Description:

Participants in the control group received routine care during intrauterine device insertion without the use of virtual reality or any additional distraction method.

No Intervention: Control Group

Arm Title Control group Arm Type No Intervention Arm Description Routine care according to the clinic's standard practice, without virtual reality or any other study intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
General Comfort Scale total score
Time Frame: Before IUD insertion (baseline) and 5 minutes after the procedure

Overall comfort was measured with the Turkish version of Kolcaba's General Comfort Scale, which consists of 48 items rated on a four-point Likert scale. Total scores range from 48 to 192, with higher scores indicating greater comfort.

Before IUD insertion (baseline) and 5 minutes after the procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
General Comfort Scale subscale scores (relief, ease and transcendence)
Time Frame: Before IUD insertion (baseline) and 5 minutes after the procedure

Scores of the relief, ease and transcendence subscales of the General Comfort Scale; higher scores indicate greater comfort.

Before IUD insertion (baseline) and 5 minutes after the procedure
Emotional state scores (tension, fear/anxiety, irritability and contentment)
Time Frame: Before IUD insertion (baseline) and 5 minutes after the procedure

Each emotional state was rated on a single-item 100-mm visual analog scale ranging from 0 (none) to 100 (most intense).

Before IUD insertion (baseline) and 5 minutes after the procedure
Pain intensity (visual analog scale)
Time Frame: Before the procedure (anticipated pain); immediately after speculum insertion, tenaculum application and IUD placement; and 5 minutes after the procedure

Pain was rated on a 100-mm visual analog scale from 0 (no pain) to 100 (worst imaginable pain). Before the procedure, women rated the pain they expected to feel during insertion (anticipated pain).

Before the procedure (anticipated pain); immediately after speculum insertion, tenaculum application and IUD placement; and 5 minutes after the procedure
Pulse rate (beats per minute
Time Frame: Before the procedure; immediately after speculum insertion, tenaculum application and IUD placement; and 5 minutes after the procedure

Pulse rate was measured by the same researcher with the same device in both groups.

Before the procedure; immediately after speculum insertion, tenaculum application and IUD placement; and 5 minutes after the procedure
Respiratory rate (breaths per minute)
Time Frame: Before the procedure and 5 minutes after the procedure

Respiratory rate was counted by the same researcher in both groups.

Before the procedure and 5 minutes after the procedure
Systolic and diastolic blood pressure (mmHg)
Time Frame: Before the procedure and 5 minutes after the procedure

Blood pressure was measured by the same researcher with the same device in both groups.

Before the procedure and 5 minutes after the procedure
Duration of IUD insertion (minutes
Time Frame: During the procedure

Time from the start to the end of the insertion procedure, recorded by the researcher in whole minutes.

During the procedure
Practitioner satisfaction with the procedure
Time Frame: Immediately after the procedure

The practitioner performing the insertion rated overall satisfaction with the procedure on a single-item 100-mm visual analog scale from 0 (not at all satisfied) to 100 (completely satisfied).

Immediately after the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Emine BAŞ, PhD, Sanko University
  • Study Chair: Zeynep GÜNGÖRMÜŞ, Prof, Gaziantep Islam Science and Technology University
  • Principal Investigator: Yasemin ATEŞEYAN, PhD, MERSİN UNIVERSITY
  • Study Chair: Esra VERİM, PhD, GAZİANTEP UNIVERSITY

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Aydın, A., Araz, A., Asan, A. 2011. Görsel Analog Ölçeği ve Duygu Kafesi: Kültürümüze Uyarlama Çalışması, Türk Psikoloji Yazıları,14 (27), 1-13.
  • Kolcaba, K. (2003). Comfort Theory and Practice A vision for holistik health care and research, Springer Publishing Company. New York
  • Kuğuoğlu, S., & Karabacak, Ü. (2008). Genel Konfor Ölçeğinin Türkçe 'ye uyarlanması. İstanbul Üniversitesi Florence Nightingale Hemşirelik Yüksekokulu Dergisi, 61(16), 16-23.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 25, 2024

Primary Completion (Actual)

March 30, 2025

Study Completion (Actual)

March 10, 2026

Study Registration Dates

First Submitted

April 17, 2026

First Submitted That Met QC Criteria

May 5, 2026

First Posted (Actual)

May 12, 2026

Study Record Updates

Last Update Posted (Actual)

November 3, 2026

Last Update Submitted That Met QC Criteria

October 30, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SANKO UNIVERSITY
  • YASEMİN ATEŞEYAN (Registry Identifier: VR-IUD)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data are available from the corresponding author upon reasonable request because of privacy and ethical restrictions.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.